Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-07 |
2024-09 |
1.66 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
1.61 |
2.01 |
0.4 |
24.84% |
2024-04-25 |
2024-03 |
-1.49 |
-1.32 |
0.17 |
11.41% |
2024-02-06 |
2023-12 |
1.76 |
1.72 |
-0.04 |
-2.27% |
2023-11-07 |
2023-09 |
1.91 |
2.29 |
0.38 |
19.90% |
2023-08-03 |
2023-06 |
1.6 |
1.34 |
-0.26 |
-16.25% |
Date |
Firm |
Action |
From |
To |
2023-09-07 |
B of A Securities |
Upgrade |
Neutral |
Buy |
2023-09-05 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-09-05 |
HSBC |
Upgrade |
|
Reduce |
2023-09-05 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-08-08 |
Benchmark |
Upgrade |
Buy |
Buy |
2023-08-03 |
RBC Capital |
Upgrade |
Sector Perform |
Sector Perform |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-07 |
BARTON JACQUELINE K |
Director |
24.54K |
Stock Award(Grant) |
2024-09-09 |
DICKINSON ANDREW D |
Chief Financial Officer |
138.92K |
Conversion of Exercise of derivative security |
2024-05-07 |
LOVE TED WENDELL |
Director |
2.82K |
Stock Award(Grant) |
2024-05-07 |
MANWANI HARISH |
Director |
12.87K |
Stock Award(Grant) |
2024-09-11 |
MERCIER JOHANNA |
Officer |
78.13K |
Sale |
2024-09-09 |
O'DAY DANIEL PATRICK |
Chief Executive Officer |
496.00K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
126.19M |
9.73B |
10.13% |
2023-06-29 |
Vanguard Group Inc |
113.37M |
8.74B |
9.10% |
2023-06-29 |
Capital World Investors |
80.93M |
6.24B |
6.50% |
2023-06-29 |
State Street Corporation |
59.32M |
4.57B |
4.76% |
2023-06-29 |
Capital Research Global Investors |
57.90M |
4.46B |
4.65% |
2023-06-29 |
Dodge & Cox Inc |
33.98M |
2.62B |
2.73% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
38.97M |
3.00B |
3.13% |
2023-09-29 |
Income Fund of America Inc |
34.44M |
2.58B |
2.76% |
2023-06-29 |
Vanguard 500 Index Fund |
29.70M |
2.29B |
2.38% |
2023-06-29 |
Dodge & Cox Stock Fund |
24.24M |
1.87B |
1.95% |
2023-08-30 |
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF |
21.14M |
1.62B |
1.70% |
2023-09-29 |
Washington Mutual Investors Fund |
20.14M |
1.51B |
1.62% |
Dividend |
Date |
0.77 |
2024-09-13 |
0.77 |
2024-06-14 |
0.77 |
2024-03-14 |
0.75 |
2023-12-14 |
0.75 |
2023-09-15 |
0.75 |
2023-09-14 |
Split |
Date |
2 : 1 |
2013-01-28 |
2 : 1 |
2007-06-25 |
2 : 1 |
2004-09-07 |
2 : 1 |
2002-03-08 |
2 : 1 |
2001-02-22 |